Skip to content

IGM Biosciences

  • About Us
    • Our Company
    • Leadership Team
  • IGM Platform
    • Our IGM Platform
    • Publications
    • Presentations
  • Pipeline & Programs
    • Pipeline
    • Imvotamab
    • IGM-8444
    • IGM-7354
    • IGM-2644
  • Investors & News
  • Join Us
    • Our Culture
    • Open Jobs
  • Contact Us

Archives: Publications

Publications

Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199

Molecular Cancer Therapeutics, October 28, 2021
Mol Cancer Ther (2021) 20 (12): 2483–2494.

Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants

Nature, June 3, 2021

Structure, Function, and Therapeutic Use of IgM Antibodies

Antibodies – Special Issue Structure and Function of Antibodies, October 13, 2020
Antibodies 2020, 9(4), 53

All content © IGM Biosciences, Inc.    info@igmbio.com    Site Credits

LinkedIn